Feasibility Study of the DragonFly-T Transcatheter Tricuspid Valve Repair System for the Treatment of Tricuspid Regurgitation
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Incidence of major adverse events (MAEs)
研究概览
简要总结
This study is a prospective design. Patients are severe tricuspid regurgitation (TR) (≥ 3+) who remained clinically symptomatic after guideline-directed medical treatment. After signing an informed consent form, subjects are enrolled and treated with the DragonFly-T Transcatheter Tricuspid Valve Repair System. All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, 12 months, and 2, 3, 4, and 5 years after the procedure.
The incidence of MAEs (Major Adverse Events) at 30 days is used as the safety endpoint. The MAEs include stroke, cardiovascular death, new renal failure, endocarditis requiring surgery, and non-elective cardiovascular interventions due to device-related adverse events.
The efficacy endpoints include acute procedural success, acute device success, the incidence of all-cause mortality and/or heart failure rehospitalization at 12 months after the procedure, the percentage of patients with tricuspid regurgitation of 2+ or less, the percentage of patients with tricuspid regurgitation reduced by at least one grade, the improvement in 6 minutes walk test, New York Heart Association (NYHA) class, quality of life change as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score and change in edema scale grading.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •In the judgment of the local cardiac team, the patient has been adequately treated according to applicable standards (including medical management), including:
- •Optimal pharmacological therapy for TR (e.g. diuretics);
- •Drug and/or interventional treatment of mitral regurgitation, atrial fibrillation, coronary artery disease, and heart failure;
- •The Eligibility Committee confirms that the patient has received adequate medical treatment.
- •Despite the drug optimization treatment according to the above method, patients still have symptoms of TR (TR grade≥3+).
- •New York Heart Association (NYHA) Cardiac function Class II-IVa.
- •The patient is suitable for transcatheter tricuspid valve repair, suitable for the use of the study device, and the femoral vein access is feasible and can accommodate a 24F catheter.
- •Patient must provide written informed consent before any steps related to the study.
排除标准
- •Tricuspid valve leaflet anatomy, which may preclude clip implantation or proper clip positioning on the leaflets, including but not limited to the following:
- •Evidence of calcification in the grasping area;
- •Presence of a severe coaptation defect of the tricuspid leaflets;
- •Severe leaflet defect(s) and cleft preventing proper device placement determined by ECL;
- •Epstein anomaly.
- •Previous tricuspid valve surgery or transcatheter therapy.
- •Echocardiography suggested intracardiac thrombus, tumor, or mass.
- •Transthoracic Echocardiogram and Transesophageal Echocardiography are unable to evaluate tricuspid valve anatomy.
- •Refractory heart failure requiring intervention (e.g., left ventricular assist device, heart transplantation) (ACC/AHA Stage D heart failure).
- •Severe and uncontrolled hypertension: systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg.
- •Active endocarditis, active rheumatic heart disease, or rheumatic heart valvular disease leading to tricuspid valve leaf lesions (poor valve leaf compliance, perforation, etc.).
- •Had myocardial infarction or unstable angina within 4 weeks; Untreated severe coronary artery stenosis requiring revascularization.
- •Percutaneous coronary intervention was performed within 30 days before surgery, except for coronary angiography.
- •Hemodynamic instability, defined as systolic blood pressure < 90mmHg, with or without cardiogenic shock, or requiring intra-aortic balloon counterpulsation or other hemodynamic support devices.
- •Bleeding diseases or coagulation disorders, or antithrombotic drug therapy contraindications.
- •Acute peptic ulcer or gastrointestinal bleeding within 3 months before surgery.
- •Severe cirrhosis (Child's grade C).
- •Allergy to the device material.
- •Life expectancy of fewer than 12 months.
- •Women who are pregnant, breastfeeding, or planning to become pregnant.
- •Participated in any drug and/or medical device clinical trials within 1 month prior to the trial.
- •The researchers do not consider it appropriate to be enrolled in the study.
结局指标
主要结局
Incidence of major adverse events (MAEs)
时间窗: 30 days
MAEs include stroke, cardiovascular death, new renal failure, endocarditis requiring surgery, and non-elective cardiovascular interventions due to device-related adverse events
次要结局
- Incidence of all-cause mortality and/or heart failure rehospitalization(12 months)
- Tricuspid regurgitation severity change(30 days, 6 months, 12 months)
- Change in 6 Minutes Walk Test(30 days, 6 months, 12 months)
- Change in NYHA class(30 days, 6 months, 12 months)
- Acute procedural success(Immediately after procedure)
- Acute device success(Immediately after procedure)
- Tricuspid regurgitation severity(30 days, 6 months, 12 months)
- Quality of life improvement(30 days, 6 months, 12 months)
- Change in edema grading(30 days, 6 months, 12 months)